6-K 1 a52956279.htm INNATE PHARMA S.A. 6-K

 

 
UNITED STATES
 SECURITIES AND EXCHANE COMMISSION
 Washington, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934
 
Date of report: For the month of November 2022

Commission File Number: 001-39084
 
Innate Pharma S.A.
 (Translation of registrant's name into English)
Innate Pharma S.A.
117 Avenue de Luminy—BP 30191
13009 Marseille, France
+ 33 (0) 4 30 30 30
(Address of principal executive office)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]
EXHIBIT INDEX
 

Exhibit
Description
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
INNATE PHARMA S.A.
 
 
 
 
 
 
Date: November 2, 2022 
By:
/s/ MONDHER MAHJOUBI
 
Name:
Mondher Mahjoubi
 
Title:
Chairman of the Executive Board and Chief Executive
 
 
Officer